Heute auf Medarex achten!

Medarex hatte heute den Start der Phase I für MDX 010 angekündigt gg. Krebs und Aids...

Grüße
Pavian  

Medarex zeiht bereits ordentlich an im deutschen Handel

Grüße
Pavian

vorbörslich bei 7 Dollar.

Press Release
                                                  Source: Medarex, Inc.


Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune
Activation by MDX-010 Published in the `Proceedings of the National Academy
of Sciences' (PNAS)
Wednesday June 25, 6:00 am ET

Complete Responses Observed in On-Going Phase II Clinical Trial

PRINCETON, N.J., June 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq:
MEDX - News) today announced the publication of positive results from the
initial cohort of 14 patients in an open-label MDX-010 Phase II melanoma study
in the Online Early Edition of the "Proceedings of the National Academy of
Sciences" (www.pnas.org) for the week of June 23, 2003. In the study, an
objective response rate of 21%, which included two complete tumor responses,
was observed in the initial cohort of 14 patients with metastatic melanoma. The
trial was conducted by Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at
the National Cancer Institute (NCI), and was the first human study designed to
assess the potential anti-tumor activity of MDX- 010, a fully human antibody that
blocks CTLA-4, after repeated dosing in combination with a peptide vaccine
based on gp100 melanoma-associated antigens. Previous studies of this
vaccine given alone without the antibody in the treatment of metastatic
melanoma demonstrated an objective response rate of approximately 2%.

                                       The data also indicates that
                                       MDX-010 may be able to induce
                                       a reversible state of
                                       autoimmunity, with an apparent
                                       correlation between the
                                       development of drug-related
                                       autoimmunity and durable clinical
                                       responses. Six patients reported
                                       drug-related autoimmune adverse
                                       events (dermatitis, colitis,
                                       hepatitis and hypophysitis), all of
                                       whom responded to medical
                                       therapy. Of the patients who
                                       experienced these Autoimmune
                                       Breakthrough Events (ABEs),
                                       50% also experienced anti-tumor
response. No patient experienced an anti-tumor response without experiencing
some ABE. The observations suggest that these drug- related adverse events,
or Autoimmune Breakthrough Events, may be associated with the induction of
anti-cancer immune responses.

In the initial cohort of 14 patients with metastatic disease, all had undergone
surgical therapy for the primary lesion and received a regimen of 3.0 mg/kg of
MDX-010 once every three weeks in combination with two peptides from the
gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-
288(288V). Of these, two patients achieved complete responses, per the
RECIST (Response Evaluation Criteria in Solid Tumors) definition. One of these
two patients experienced complete resolution of a 0.5 cm brain lesion, two
subcutaneous nodules and 31 lung metastases. The second of these two
patients experienced complete resolution of an abdominal subcutaneous nodule
and a solitary lung lesion. Prior to treatment with the MDX-010 antibody and
gp100 peptide vaccine, both patients had received chemotherapy and
undergone surgical therapy, and one patient had also received previous
immunotherapy. A third patient who had received previous immunotherapy
achieved a partial response with tumor shrinkage of a solitary lung lesion,
lasting over 10 months after two treatment cycles. Mixed responses were
observed in two additional patients.

These results were recently presented at the 2003 annual meeting of the
American Society of Clinical Oncology (ASCO 2003 Abstract #3424). The
ongoing Phase II trial is expected to enroll up to 55 patients.

"We are excited by these significant anti-tumor responses in metastatic disease
and by the apparent correlation of tumor responses with the advent of
Autoimmune Breakthrough Events," said Geoffrey M. Nichol, M.D., Senior Vice
President of Product Development at Medarex. "We believe that these
preliminary results demonstrate the potential of MDX-010 to break tolerance to
self in a predictable and reversible fashion and that during this temporary
autoimmune state, useful anti-tumor effects can be seen. The ABEs themselves
are markedly less troublesome than the adverse event profiles observed in the
current forms of standard melanoma treatment."

"We believe that MDX-010 has the potential to become a significant treatment
for melanoma and other serious diseases," said Donald L. Drakeman,
President and CEO of Medarex. "We are greatly encouraged that some
patients with metastatic disease still appear cancer-free, and we look forward to
additional data later in the year that may further demonstrate the benefits of
MDX-010 in patients."

MDX-010 is currently in multiple Phase II clinical trials to test the product for use
in patients with melanoma and prostate cancer. MDX-010 is also being tested
in a Phase I clinical trial for HIV.


chart.bigcharts.com/bc3/quickchart/...416&mocktick=1&rand=875" style="max-width:560px" >

Medarex (WKN: 883040, US: MEDX) wird Anleihen mit einer Laufzeit bis 2010 im Wert von $100 Millionen an qualifizierte institutionelle Investoren verkaufen. Der Erlös soll für allgemeine Geschäftszwecke, darunter auch mögliche Akquisitionen und die Refinanzierung von Krediten, verwendet werden. Die Aktie schloss bei $7.03.

© BörseGo

Medarex (WKN: 883040, US: MEDX) wird Anleihen mit einer Laufzeit bis 2010 im Wert von $100 Millionen an qualifizierte institutionelle Investoren verkaufen. Der Erlös soll für allgemeine Geschäftszwecke, darunter auch mögliche Akquisitionen und die Refinanzierung von Krediten, verwendet werden. Die Aktie schloss bei $7.03.

Quelle: BörseGo

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; "could"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in Medarex''s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2002 and subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex''s public disclosure filings are available from its investor relations department.

Medarex, Inc.

© PR Newswire

Medarex scheint sehr fortschrittlich in Sachen SARS zu sein, da der Virus immer noch nicht endgültig besiegt ist, birgt das meiner meineung nach reichlich Kurspotential